journal article·2018-09

Inhibition of the fibrillation of highly amyloidogenic human calcitonin by cucurbit[7]uril with improved bioactivity

Hui Shang, Anna Zhou, Jian Jiang, Yanpeng Liu, Jing Xie, Sheyu Li, Yantao Chen, Xiaofeng Zhu, Hong Tan, Jianshu Li

Acta Biomaterialia· Volume 78
Publisher page

Abstract

Protein/peptide fibrillation is an important challenge for biotechnological drug development. Salmon calcitonin (sCT) is currently used in the clinical treatment of bone-related diseases such as osteoporosis and hypercalcemia, but it still has the risk of immune responses. Although human calcitonin (hCT) would be a better choice in terms of immunogenicity, it has a strong tendency to irreversibly aggregate in aqueous solutions and form long amyloid fibrils, which significantly reduces its bioavailability and therapeutic potency. Here, we demonstrate that cucurbit[7]uril (CB[7]) can inhibit hCT fibrillation by supramolecular interaction with its aromatic groups (affinity: Phe16 > Tyr12 > Phe19 > Phe22). The hCT-CB[7] complex exhibits low cytotoxicity, even promotes osteoblast proliferation and osteogenic capacity of MC3T3 cells. Meanwhile the hCT-CB[7] complexes shows higher bioactivity compared to hCT in reducing blood calcium levels in rats, and also decreases the immunogenicity of hCT. These results suggest that CB[7] has the potential to improve the therapeutic potency of amyloidogenic protein/peptide drugs such as hCT.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Crystallography and molecular interactions · RNA and protein synthesis mechanisms · Protein Structure and Dynamics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (60)

Show source-provided references
1. Protein aggregation—pathways and influencing factors10.1016/j.ijpharm.2010.02.025 ↗
2. Structure of the cross-beta spine of amyloid-like fibrils10.1038/nature03680 ↗
3. Protein misfolding, functional amyloid, and human disease10.1146/annurev.biochem.75.101304.123901 ↗
4. Review: modulating factors in amyloid-beta fibril formation10.1006/jsbi.2000.4289 ↗
5. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases10.1038/416507a ↗
6. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution10.1007/s00109-003-0464-5 ↗
7. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis10.1126/science.1079469 ↗
8. On the structural definition of amyloid fibrils and other polypeptide aggregates10.1007/s00018-007-7110-2 ↗
9. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis10.1210/er.2007-0037 ↗
10. Calcitonin-like immunoreactivity of amyloid fibrils in medullary thyroid carcinomas10.1007/BF00844290 ↗
11. Pathophysiology and treatment of systemic amyloidosis10.1038/nrneph.2013.171 ↗
12. Structure-immunogenicity relationships of therapeutic proteins10.1023/B:PHAM.0000029275.41323.a6 ↗
13. Effects of protein aggregates: an immunologic perspective10.1208/aapsj080359 ↗
14. Dysfunction of constitutive and inducible ubiquitin-proteasome system in amyotrophic lateral sclerosis: implication for protein aggregation and immune response10.1016/j.pneurobio.2011.10.001 ↗
15. Immunogenicity of therapeutic proteins: clinical implications and future prospects10.1016/S0149-2918(02)80075-3 ↗
16. Supramolecular nanoparticles of calcitonin and dipeptide for long-term controlled release10.1016/j.jconrel.2017.04.014 ↗
17. An evaluation of antibodies and clinical resistance to salmon calcitonin10.1172/JCI107044 ↗
18. Amino acid sequence of salmon ultimo branchial calcitonin10.1073/pnas.64.2.771 ↗
19. Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis10.1007/BF01880446 ↗
20. Calcitonin - a review of experimental and clinical investigations10.1136/pgmj.44.511.411 ↗
21. Amyloid fibril formation by pentapeptide and tetrapeptide fragments of human calcitonin10.1074/jbc.M206039200 ↗
22. NMR characterization of monomeric and oligomeric conformations of human calcitonin and its interaction with EGCG10.1016/j.jmb.2011.12.023 ↗
23. Converting the highly amyloidogenic human calcitonin into a powerful fibril inhibitor by three-dimensional structure homology with a non-amyloidogenic analogue10.1074/jbc.M110.182014 ↗
24. Specific mutations alter fibrillation kinetics, fiber morphologies, and membrane interactions of pentapeptides derived from human calcitonin10.1021/bi1002713 ↗
25. Enhanced physical stability of human calcitonin after methionine oxidation10.1016/j.ejpb.2010.12.038 ↗
26. The cucurbit[n]uril family10.1002/anie.200460675 ↗
27. Molecular recognition of insulin by a synthetic receptor10.1021/ja201581x ↗
28. Supramolecular enhancement of protein analysis via the recognition of phenylalanine with cucurbit[7]uril10.1021/jacs.5b10648 ↗
29. Sequence recognition and self-sorting of a dipeptide by cucurbit[6]uril and cucurbit[7]uril10.1039/b719902c ↗
30. Cucurbituril-based molecular recognition10.1021/acs.chemrev.5b00341 ↗
31. Supramolecular amphiphiles based on host-guest molecular recognition motifs10.1021/cr5005315 ↗
32. Protein recognition using synthetic small-molecular binders toward optical protein sensing in vitro and in live cells10.1039/C4CS00381K ↗
33. Supramolecular inhibition of amyloid fibrillation by cucurbit[7]uril10.1002/anie.201402496 ↗
34. Cucurbit[7]-assisted sustained release of human calcitonin from thermosensitive block copolymer hydrogel10.1016/j.ijpharm.2017.05.006 ↗
35. The structure and mechanism of formation of human calcitonin fibrils10.1016/S0021-9258(18)53268-3 ↗
36. Metadynamics: a method to simulate rare events and reconstruct the free energy in biophysics, chemistry and material science10.1088/0034-4885/71/12/126601 ↗
37. A bias-exchange approach to protein folding10.1021/jp067873l ↗
38. On the accuracy of metadynamics and its variations in a protein folding process10.1080/08927022.2014.931680 ↗
39. Atomistic picture for the folding pathway of a hybrid-1 type human telomeric DNA G-quadruplex10.1371/journal.pcbi.1003562 ↗
40. A bias-exchange approach to protein folding10.1021/jp067873l ↗
41. Defining the molecular basis of amyloid inhibitors: human islet amyloid polypeptide-insulin interactions10.1021/ja504031d ↗
42. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit10.1093/bioinformatics/btt055 ↗
43. GROMACS: fast, flexible, and free10.1002/jcc.20291 ↗
44. PLUMED 2: New feathers for an old bird10.1016/j.cpc.2013.09.018 ↗
45. PLUMED: a portable plugin for free-energy calculations with molecular dynamics10.1016/j.cpc.2009.05.011 ↗
46. Improved side-chain torsion potentials for the Amber ff99SB protein force field10.1002/prot.22711 ↗
47. Bridging calorimetry and simulation through precise calculations of Cucurbituril-guest binding enthalpies10.1021/ct5004109 ↗
48. ACPYPE - AnteChamber PYthon Parser interface10.1186/1756-0500-5-367 ↗
49. Menschliches calcitonin VI1
50. Amyloids protect the silkmoth oocyte and embryo10.1016/S0014-5793(00)01888-3 ↗
51. Inhibitory effects of magnolol and honokiol on human calcitonin aggregation10.1038/srep13556 ↗
52. Quantification of apoptosis and necroptosis at the single cell level by a combination of Imaging Flow Cytometry with classical Annexin V/propidium iodide staining10.1016/j.jim.2015.04.025 ↗
53. Effects of silicon on osteoblast activity and bone mineralization of MC3T3-E1 cells10.1007/s12011-012-9593-4 ↗
54. Effects of continuous passaging on mineralization of MC3T3-E1 cells with improved osteogenic culture protocol10.1089/ten.tec.2012.0412 ↗
55. Thermosensitive drug delivery system of salmon calcitonin: in vitro release, in vivo absorption, bioactivity and therapeutic efficacies10.1007/s11095-009-0015-z ↗
56. Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy10.1016/S0022-3565(24)37553-6 ↗
57. Pharmacokinetic/pharmacodynamic relationship of marbofloxacin against Aeromonas hydrophila in Chinese soft-shelled turtles (Trionyx sinensis)10.1111/jvp.12214 ↗
58. Rare causes of hypercalcemia10.1210/jc.2005-0675 ↗
59. Cancer-induced hypercalcemia
60. Forty years of calcitonin-where are we now? A tribute to the work of Iain Macintyre10.1016/S8756-3282(02)00688-9 ↗